is the uk's £33 million going to a trial of metformin and atomoxetine in alzheimer's?
“the government has uh put up 33 million pounds 44 million to begin a study of two medicines in the treatment of Alzheimer's disease.”
a guest, a neurologist said on The Diary of a CEO, 2026-11-12, at 08:30. hear it in context →
first, the part that holds
the trial is real and the drugs are right. AD-SMART is a UK phase 3 platform trial that tests metformin and atomoxetine against a placebo in people with Alzheimer's disease. Its main results are measured at 18 months, and it is government-backed in part.
what we found when we went and looked
the trial registry and the paper that picked the drugs bear out the medical details: metformin and atomoxetine against a shared placebo, with the main results measured at 18 months. The recruitment target is 1,200, not about 1,000. The £33 million is a real government figure, but it isn't the budget of this study. The UK government's own dementia goals page says the £33 million is government money behind a £48 million partnership on biomarkers, data, faster trials and regulators, with £15 million more from industry. A minister repeated that figure in the trial's launch announcement, which is likely where the link came from. No primary record we found gives a £ amount for AD-SMART. The trial is led and funded by a national dementia research institute and a dementia research charity, with the government's health research funder as a partner and government funding promised without a figure.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the UK government put up about £33 million (stated in the quote as '33 million pounds, 44 million') to begin this study of two medicines | misattributed | the gov.uk dementia goals page (updated 23 october 2026) says '£48 million UK-wide not-for-profit partnership ... backed by £33 million of Government investment and £15 million from' three industry and philanthropy partners. The partnership's remit is biomarkers, data and digital sciences, faster clinical trials and support for regulators. That page never mentions AD-SMART. A june 2026 government letter promises 'increased funding for the AD-SMART trial' but gives no amount. The trial's launch release says it is funded by a national dementia research institute and a dementia research charity, with 'ongoing funding committed by UK government', and quotes a minister on the £33 million programme without saying it pays for the trial. We found no record of any 44 million figure. It may be a rough dollar conversion of £33 million, but that is our guess. Limit: we could not search the full grant databases. [1][2][4] |
| the trial tests metformin and atomoxetine (an ADHD drug) in Alzheimer's disease | confirmed | registry NCT07724132 lists three arms in a 1:1:1 split: placebo, atomoxetine up to 100 mg/day, and immediate-release metformin up to 2,000 mg/day, each on top of standard care. People must be 55 or older, have a biomarker-supported diagnosis of Alzheimer's or mixed dementia, and score 17 or more on the MMSE memory test. A paper funded by the government's health research funder ranked atomoxetine first and metformin second out of the candidate drugs. [3] |
| about 1,000 patients | undersold | the registry lists an estimated enrollment of 1,200 for the first two drugs plus placebo, so the real target is a bit larger than claimed. This is a recruitment target, not people already enrolled. The trial opened in late 2026 and its sites will open over the next 12 to 18 months. |
| over 18 months | confirmed | the registry's two main measures are change in thinking (ADAS-Cog) and in daily living (A-IADL-Q-SV) from the start to 18 months, checked at 6, 12 and 18 months. 18 months is how long each person is followed. The trial as a whole is expected to finish judging the first drugs around 2030, and the registry gives march 2031 as the completion date. |
both directions
for the speaker: the drugs, the disease, the 18-month follow-up and the role of public money all hold up. Two government records connect the government to the trial: a june 2026 letter that promises 'increased funding for the AD-SMART trial', and a september 2026 speech by a minister about 'furthering our investment in the AD-SMART platform trial'. The government's health research funder is listed as a collaborator on the registry and paid for the work that picked the drugs. The £33 million figure is real, and it was mentioned at the trial's launch.
against: no government document we read says the £33 million pays for AD-SMART. The gov.uk dementia goals page ties the £33 million to a separate £48 million partnership with a broad research remit, and it does not name AD-SMART. The trial's own launch release says it is funded by a dementia research institute and a charity. The government's part is described only as 'ongoing funding', with no figure. Calling the trial 'a £33 million government study of two medicines' joins a programme-level number onto one trial. The trial also aims to enrol 1,200 people, not about 1,000. And it is a platform trial, built to add more drugs over time, so it is not just a study of two medicines.
what this cannot say
we did not find a public £ budget for AD-SMART, so we cannot rule out that some of the £33 million flows to it in part. What we can say is that no primary record we read states that. We could not search the government's grant award database or the charity's grant records directly. The trial details come from the ClinicalTrials.gov registry entry, and the figures there are estimates that can change. The '44 million' in the quote matches no record we found. The trial has just opened, so nothing here says whether either drug works in Alzheimer's disease.
the medication pages behind this check
sources, each one fetched and read
- UK Government, Life Sciences Healthcare Goals: dementia goals programme, gov.uk, updated 23 October 2026 What we read there: 'a £48 million UK-wide not-for-profit partnership ... backed by £33 million of Government investment and £15 million from' industry and philanthropy partners; the remit is biomarkers, data and digital sciences, faster clinical trials and regulator support; AD-SMART, metformin and atomoxetine are not mentioned Fetched 2026-11-13 (HTTP 200). https://www.gov.uk/government/publications/life-sciences-healthcare-goals/dame-barbara-windsor-dementia-goals
- Department of Health and Social Care, letter on progress on adult social care reform recommendations, gov.uk, 22 June 2026 What we read there: lists 'increased funding for the AD-SMART trial' among its dementia measures; no £ amount anywhere on the page Fetched 2026-11-13 (HTTP 200). https://www.gov.uk/government/publications/letter-to-baroness-casey-progress-on-adult-social-care-reform-recommendations/letter-to-baroness-casey-progress-on-adult-social-care-reform-recommendations
- Repurposed Drug Prioritisation Pipeline for an Alzheimer's Disease Multi-arm Platform Trial, PMC12740648 What we read there: 'Funded by the UK National Institute of Health and Care Research.' Atomoxetine ranked first, metformin second, isosorbide mononitrate and levetiracetam joint third; the target population is clinical Alzheimer's with MMSE >17; no £ amounts Fetched 2026-11-13 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC12740648/
- Minister of State for Social Care and Mental Health, speech on dementia, gov.uk, 17 September 2026 What we read there: 'furthering our investment in the AD-SMART platform trial and standing up the next phase of the Dementia Trials Accelerator'; no £ figure for AD-SMART; metformin and atomoxetine not mentioned Fetched 2026-11-13 (HTTP 200). https://www.gov.uk/government/speeches/minister-of-state-for-social-care-and-mental-health-speech-on-dementia
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam